RenovoRx, Inc.

General Information

(Note: IPOScoop has NO Call on this micro-cap unit offering. Each unit consists of one share of common stock and one warrant to buy one share of common stock.)

We are a clinical biopharmaceutical company whose first product candidate, RenovoGem, is a drug and device combination of intra-arterial gemcitabine and RenovoCath. The FDA has granted orphan drug designation for RenovoGem for our first two indications – pancreatic cancer and bile duct cancer.

**The revenue and net loss figures are for the 12 months that ended June 30, 2021.

(Note: RenovoRx priced its IPO on Aug. 25, 2021, at $9 – the low end of its $9-to-$11 range – and sold 1.85 million units, up from 1.8 million units in its prospectus, to raise $16.65 million. RenovoRx had downsized its IPO to 1.8 million units – down from 1.85 million – and cut the price range to $9 to $11 – down from $11 to $13 – in an S-1/A filing dated Aug. 25, 2021.)

Employees: 7
Founded: 2012
Contact Information
Address 546 El Camino Real, Suite B1 Los Altos, CA 94022
Phone Number (650)-284-4433
Web Address
View Prospectus: RenovoRx, Inc.
Financial Information
Market Cap $82.63mil
Revenues $0 mil (last 12 months)
Net Income $-4.43 mil (last 12 months)
IPO Profile
Symbol RNXT
Exchange NASDAQ
Shares (millions): 1.9
Price range $9.00 - $9.00
Est. $ Volume $16.7 mil
Manager / Joint Managers Roth Capital Partners / Maxim Group
CO-Managers -
Expected To Trade: 8/26/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change